Activity of 2-aryl-2-(3-indolyl)acetohydroxamates against drug-resistant cancer cells

Area of Science:

• Medicinal Chemistry
• Oncology
• Drug Discovery

Background:

• Many cancers, including glioma, melanoma, lung, esophageal, and head and neck cancers, exhibit intrinsic resistance to apoptosis induction.
• Tumors frequently develop multidrug resistance (MDR) through mechanisms like enhanced cellular efflux of chemotherapeutic agents.
• There is a critical need for novel anticancer agents that can overcome these resistance mechanisms and improve therapeutic outcomes.

Purpose of the Study:

• To identify and characterize novel chemical scaffolds with potential anticancer activity.
• To evaluate the efficacy of a series of 2-aryl-2-(3-indolyl)acetohydroxamic acids against resistant cancer cell lines.
• To explore the potential of these compounds in overcoming apoptosis and multidrug resistance in cancer.

Main Methods:

• Synthesis of a series of 2-aryl-2-(3-indolyl)acetohydroxamic acids.
• In vitro evaluation of compound activity against apoptosis-resistant and multidrug-resistant cancer cell lines.
• Testing against patient-derived glioblastoma neurosphere stem-like cell cultures.

Main Results:

• The synthesized 2-aryl-2-(3-indolyl)acetohydroxamic acids demonstrated significant activity against apoptosis-resistant cancer cells.
• These compounds were also effective against multidrug-resistant cancer cell lines.
• Activity was observed in glioblastoma neurosphere stem-like cell cultures, indicating potential against brain tumors.

Conclusions:

• The 2-aryl-2-(3-indolyl)acetohydroxamic acid series represents a promising novel chemical scaffold for anticancer drug development.
• These compounds show potential for overcoming key cancer resistance mechanisms, including apoptosis and multidrug resistance.
• Further development of these compounds could lead to highly effective clinical cancer drugs.